It is now well established that any given ligand for a G-protein coupled receptor (GPCR) does not simply possess a single defined efficacy. Rather, a ligand possesses multiple efficacies, depending on the specific down-stream signal transduction pathway analyzed. This diversity may be based on ligand-specific GPCR conformations and is often referred to as "Functional Selectivity". It has been known for a century that stereoisomers of catecholamines differ in their potency, and in some systems, also in their efficacy. However, the molecular basis for efficacy differences of GPCR ligand stereoisomers has remained poorly defined. In an elegant study published in this issue of Molecular Pharmacology, Woo et al. show that stereosiomers of the 2 -adrenoceptor selective agonist fenoterol differentially activate G s -and G i -proteins in native rat cardiomyocytes. This study is so important because it is the first report to show that even the subtle structural differences within a ligand stereoisomer pair are sufficient to discriminate between GPCR conformations with distinct G-protein coupling properties. The study highlights of how important it is to examine the "more active" (eutomer) and the "less active" (distomer) stereoisomer to understand the mechanisms of action and the cellular effects of GPCR ligands. The study by the Xiao group will ignite a renaissance of the analysis of ligand stereoisomers, using sensitive pharmacological and biophysical assays.
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5 by the adrenal medulla, and (-)-norepinephrine, a neurotransmitter, are the endogenous ligands of the 2 AR. The 2 AR is a classic G s -coupled GPCR, triggering activation of adenylyl cyclase with subsequent cAMP production. In 1995, Xiao et al. made the most intriguing observation that pertussis toxin, ADP-ribosylating G i -protein -subunits and, thereby, uncoupling GPCRs from G i , enhanced 2 AR-mediated positive inotropic effects in isolated rat cardiomyocytes. These data suggested that in addition to G s , the 2 AR also couples to G i -proteins in native systems. Then, in 2003, Xiao et al. noted that the positive inotropic responses towards most 2 AR agonists such as zinterol, salbutamol (albuterol) and procaterol were enhanced by pertussis toxin pretreatment, whereas the effects of fenoterol were not affected. These findings were the first indication that fenoterol may stabilize a unique 2 AR conformation promoting a distinct pattern of G-protein activation.
Different efficacies of GPCR ligand stereoisomers. It has been known for a century that the naturally occurring (-)-stereoisomer of epinephrine constricts blood vessels more potently than (+)-epinephrine (Cushny, 1908) . Since then, a large number of studies has elaborated the concept that (-)-stereoisomers of catecholamines bind to adrenergic receptors with higher affinity and activate the receptors with higher potency than the corresponding (+)-stereoisomers. This concept has recently been covered in an excellent review (Patil et al., 2008) .
Intriguingly, some studies did not only report differences in affinity/potency between stereoisomers but also differences in efficacy. Specifically, (-)-norepinephrine induces a slow conformational change in purified 2 AR, whereas (+)-norepinephrine is inactive in this respect (Swaminath et al., 2004) . Additionally, in the presence of inosine-5'-triphosphate or xanthosine-5'-triphosphate, but not in the 6 presence of guanosine-5'-triphosphate (GTP), (+)-isoproterenol is less efficacious than (-)-isoproterenol at activating adenylyl cyclase by a 2 AR-G s fusion protein (Seifert et al., 1999) . There are also striking differences in the efficacies of (-)-and (+)-isoproterenol at stabilizing high-affinity agonist binding, i.e. ternary complex formation, in a constitutively activate 2 AR mutant ( 2 AR CAM ) (Seifert et al., 2001 ).
Moreover, differences in efficacy between (-)-and (+)-epinephrine were observed in native tissues and cell membranes (Kim et al., 1981; Patil et al., 1996) . Beyond catecholamines, dexmedetomidine is a partial 2A -adrenergic receptor agonist, whereas the other stereoisomer, levomedetomidine, acts as inverse agonist, i.e. a ligand that stabilizes the inactive (R) state of the GPCR (Jansson et al., 1998) .
Furthermore, stereoisomers of chiraprodifens, a new class of potent synthetic histamine H 1 -receptor agonists, exhibit striking species-specific pharmacological properties at the human, rat, guinea big and bovine H 1 -receptor (Strasser et al., 2008) . Collectively, all these data provide the basis for the concept that stereoisomers of a given ligand stabilize functionally distinct GPCR conformations.
Differential G s -and G i -protein activation by fenoterol stereoisomers. The analysis of the unique effects of fenoterol in cardiomyocytes was complicated by the fact that the compound possesses two chirality centers, yielding four fenoterol stereoisomers, referred to as R,R-, R,S-S,R-, and S,S-fenoterol (Jozwiak et al., 2007) . The study of Woo et al. focused on the analysis of R,R-and S,R-fenoterol, and the fenoterol derivatives, R,R-methoxyfenoterol and S,R-methoxyfenoterol in isolated rat cardiomyocytes. The compounds studied exhibit selectivity for the 2 AR relative to the 1 AR, and the R,R-stereoisomers possess considerably higher affinity for the 2 AR than the S,R-stereoisomers (Jozwiak et al., 2007) . R,R-and S,RThis article has not been copyedited and formatted. The final version may differ from this version. fenoterol are similarly efficacious at increasing contractility of the cardiomyocytes via the 2 AR. Most strikingly, pertussis toxin shifts the contraction concentrationresponse curve for S,R-fenoterol to the left, whereas the stimulatory effects of R,Rfenoterol are unaffected by the toxin. Moreover, S,R-fenoterol stimulates extracellular signal-regulated kinase (ERK) phosphorylation in a pertussis toxin-sensitive fashion, whereas the stimulatory effects of the corresponding R,R-stereoisomers are pertussis toxin-insensitive. These data indicate that R,R-fenoterol activates only G s -proteins, whereas and S,R-fenoterol activates both G i and G s (Fig. 1) . This interpretation is supported by G-protein photoaffinity labeling experiments. Specifically, R,R-fenoterol is more effective at stimulating the incorporation of [ -32 P]GTP azidoanilide into G s than S,R-fenoterol, whereas only S,R-fenoterol stimulates photoaffinity labeling of G i 2 . G i 2 is the predominant pertussis toxin-sensitive G-protein in the heart. Thus, the previously noted PTX-insensitivity of the effects of racemic fenoterol in cardiomyocytes (Xiao et al., 2003) could be explained by the fact that the higher potency of R,R-fenoterol at the 2 AR for G s masked the effect of S,R-fenoterol, possessing a lower potency for G s and G i (Fig. 1 ). These data show that it is sometimes misleading to use the evaluative terms eutomer and distomer (introduced by E. J. Ariëns for the more and less potent stereoisomer, respectively) which are by definition based on a particular affinity and/or potency. However, the distomer may actually possess more interesting and important pharmacological properties than the eutomer (Fig. 1 ).
There are some intriguing pharmacological differences in the effects of the that can be considered as physiologically highly relevant. In support of the concept developed in this study are previous data from our laboratory using a recombinant expression system. Particularly, the potencies and efficacies of a series of "standard" Wenzel-Seifert and Seifert, 2000) . However, in our previous study we missed the unique opportunity to dissect differences in G-protein coupling of ligand stereoisomers because we deemed this possibility as too unlikely, trying to "focus" our study on the supposedly "important" ligands. This is an excellent example of how wrong a priori probability assumptions can delay scientific progress for several years.
This article has not been copyedited and formatted. The final version may differ from this version. can activate G i in terms of guanine nucleotide exchange to some extent without the apparent need for additional proteins and phosphorylation reactions (Asano et al., 1984; Cerione et al., 1985) . In agreement with these data, the analysis of 2 AR coexpressed with G i 2 and of a 2 AR-G i 2 fusion protein in Sf9 insect cell membranes revealed that the 2 AR activates G i 2 more sluggishly than classic G i -coupled receptors such as the formyl peptide receptor (Wenzel- Seifert and Seifert, 2000) . In contrast, an alternative hypothesis had proposed that 2 AR-G i -coupling depends on protein kinase A-mediated 2 AR phosphorylation (Daaka et al., 1997; Zamah et al., 2002) . However, analysis of a 2 AR mutant devoid of protein kinase A phosphorylation sites did not support the latter hypothesis (Friedman et al., 2002 However, so far, only the crystal structure of the 2 AR bound to an inverse agonist, carazolol, could be resolved Cherezov et al., 2007) ). Given the high conformational flexibility and instability of the 2 AR, it will be a formidable challenge to obtain high-resolution 2 AR crystals bound to fenoterol. Perhaps this goal can be accomplished by generating 2 AR-G (peptide) crystals as has been very recently shown for rhodopsin (Scheerer et al., 2008) . It is certainly feasible to obtain insights into the mechanism of action of fenoterol stereoisomers by studying all steps of the G-protein cycle with 2 AR-G fusion proteins (Wenzel-Seifert and Seifert, 2000; Weitl and Seifert, 2008) at high sensitivity and to conduct fluorescence spectroscopy studies with purified 2 AR (Swaminath et al., 2004) . In addition, molecular modeling of the 2 AR ligand binding site based on the available crystal structures is possible (Audet and Bouvier, 2008) .
Although the high-resolution 2 AR crystal structure probably represents an inactive receptor state, docking of the fenoterol stereoisomers may provide suggestions about possible reasons for functional selectivity. respectively, in TM5. Both serines are critical for catecholamine binding and 2 AR activation (Strader et al., 1989) .
In summary, the model in Figure 2A suggests a very tight binding of R,Rfenoterol to the 2 AR which is in particular based on seven hydrogen bonds. S,Rfenoterol can principally bind in a similar mode and conformation (see Figure 2B ).
However, the interactions with the 2 AR are weaker compared to the R,R- interacting more or less selectively with G s , G i 2 , or G i 3 . I.e., ligand-specific inactive GPCR conformations are no necessary condition for promiscuous G protein coupling.
This hypothesis must be further substantiated by molecular dynamics simulations and can be verified only by crystal structures of active GPCR states. A first milestone on this long way has been very recently set by the release of an opsin structure in its G-protein-interacting conformation (Scheerer et al., 2008) , showing an outward tilt of TM6 and a pairing of TMs 5 and 6.
Some future studies. R,R-Fenoterol is a G s -selective full 2 AR agonist, whereas S,R-fenoterol is a partial 2 AR agonist with respect to G s -activation and a full agonist with respect to G i 2 -activation (Fig. 1 ). It will be important to develop G iselective 2 AR agonists in order to learn more about the as yet elusive (patho)physiological relevance of the 2 AR-activated G i pathway in cardiomyocytes and other systems such as bronchial smooth muscle cells. This will not be trivial since to this end, the potency of most 2 AR agonists for the G i pathway is considerably lower than for the G s pathway (Wenzel-Seifert and Seifert, 2000) .
Moreover, high potency of G i -selective 2 AR agonists would be most welcome in order to avoid potential ligand interactions with the 1 AR and 3 AR. Future studies will also have to address the question whether in addition to G s and G i , fenoterol stereoisomers differentially activate pertussis toxin-sensitive G q -proteins that mediate phospholipase C activation. The necessity for such studies comes from the finding that the stimulatory effects of the four fenoterol stereoisomers examined exhibit striking differential and partial pertussis toxin-insensitivity which is not discussed in the paper by Woo et al., however. Previous studies from our laboratory had already shown that the pharmacological profile of the 2 AR coupled to G q -proteins differs This article has not been copyedited and formatted. The final version may differ from this version. from the profile of the G s -and G i -coupled 2 AR, although G q -coupling was rather poor in our hands (Wenzel-Seifert and Seifert, 2000) . It will also be necessary to study the impact of G-protein x y -complexes on G -selectivity of fenoterol stereoisomers. Particularly, the stereosiomers differ remarkably from each other in terms of G s activation, but in terms of 2 AR phosphorylation, they are quite similar.
An explanation for this discrepancy could be the recruitment of different G x ycomplexes by the various stereoisomers, compensating for the differences observed with respect to G s activation.
The current study by Woo et al. focuses on efficacies of fenoterol stereoisomers with regard to the various parameters. While this is sufficient to support the main hypothesis of the paper, future studies should also careful examine agonist potencies since it is well possible that a given ligand does not only possess multiple efficacies but also multiple affinities for the various receptor conformations, depending on the specific parameter analyzed. These studies will bring us a step closer to the goal of achieving ligand-specific activation of G -protein subtypes.
Multiple parameter-dependent affinities/potencies of a given ligand for the 2 AR have been observed before (Seifert et al., 1999 (Seifert et al., , 2001 Weitl and Seifert, 2008) .
Elegant studies with opioid receptors have shown that various ligands differ from each other in their membrane and cell compartment trafficking (Hanyaloglu and von Zastrow, 2008) . Thus, it is conceivable that fenoterol stereoisomers show differences in 2 AR trafficking as well. Specifically, resistance of fenoterol/ 2 AR complexes to desensitization and internalization may occur since long-term treatment with fenoterol in a heart failure model is not associated with a loss of efficacy (Ahmet et al., 2008) . In this context, it will also be interesting to examine the effects of This article has not been copyedited and formatted. The final version may differ from this version. program dealing with stereoisomers should not only search for "more active" highpotency eutomers, but also for "less active" low-potency distomers (Fig. 1) . Moreover, it is prudent to study at least two independent read-outs for each GPCR, preferably mediated by different G-proteins. And even for GPCRs that couple only to one cognate G-protein, it is advisable to determine several read-outs at various steps of the G-protein cycle since differences of ligand potencies and efficacies for the various parameters within the cycle can be substantial, even if endogenous agonists are considered (Seifert et al., 1999 (Seifert et al., , 2001 Weitl and Seifert, 2008) . On first glance, this may sound like bad news since initially, a drug development program will become more complicated, expensive and time-consuming. However, on second glance, the return may be novel interesting drugs that would have been missed using standard approaches aiming only at high-potency ligands and measuring only one single readout.. We have missed such a great opportunity in our laboratory several years ago (Wenzel-Seifert and Seifert, 2000) .
Clinical implications. The present study has important clinical implications.
Specifically, fenoterol is widely used for the treatment of acute asthma attacks, and uncritical use of racemic fenoterol is associated with increased mortality of asthma patients (Jalba, 2008) . Thus, clinical studies will have to answer the question whether specific fenoterol stereoisomers, through their unique pattern of G-protein activation, possess clinically relevant differences in terms of therapeutic efficacy and toxicity.
Along the same line, albuterol possesses a chirality center (Boulton and Fawcett, This article has not been copyedited and formatted. The final version may differ from this version. (Seifert et al., 1999 (Seifert et al., , 2001 Wenzel-Seifert and Seifert, 2000) . The reason for this situation is simply the limited stereoisomer availability to the pharmacological community.
Another potential application of 2 AR agonists is the treatment of heart failure as adjunct to 1 AR antagonists. Specifically, in a rat model of dilated cardiomyopathy, In this context, it will also be very interesting and important to determine whether fenoterol stereoisomers interact differentially with the various human 2 AR polymorphic isoforms (Brodde, 2008) .
This article has not been copyedited and formatted. The final version may differ from this version. Conclusions. The current study by the Xiao group corroborates the concept of ligand-specific GPCR conformations, resulting in differential G-protein activation or, in more general terms, functional selectivity. Ligand stereoisomers are important experimental tools to examine mechanisms of GPCR activation and signal transduction pathways. The present study should encourage pharmacologists to systematically examine the "more active" eutomer and the "less active" distomer of a given ligand and not only to focus on more readily available racemic ligands or "eutomers". We anticipate that analysis of ligand stereoisomers with modern pharmacological and biophysical methods will be a goldmine and yield important data, ultimately improving clinical drug therapy and reducing drug toxicity. 
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